From selecting appropriate patients for clinical studies, to identifying the right endpoints and biomarkers, 2023 was marked with the very first disease-modifying treatments for Alzheimer’s disease. Looking ahead in 2024, the field is poised to do an even better job of slowing the relentless disease progression of Alzheimer’s disease.

 

As we gear up for 2024, Prothenians shared what they are looking forward to most in the year to come.

 

“In this dynamic biotechnology space, great strides were made with the recent approvals of new treatment options for patients with neurodegenerative diseases.  I look forward to another exciting year not only for Prothena but also for the field to generate potentially transformational data in 2024 and beyond. I am proud to do my part and contribute to this progress.” — Lenh Mong, Regulatory Affairs

 

“As someone who’s been with Prothena since the beginning, I am most looking forward to seeing the long-awaited clinical fruits of our R&D efforts for Alzheimer’s disease, Parkinson’s disease, and AL amyloidosis patients.” — Stephen Tam, Cell Biology

 

“In 2024, I look forward to continuing to keep the patient at the center of everything we do, as we look to bring meaningful solutions to those impacted by rare peripheral diseases. By listening to patients, learning from physicians, and partnering with colleagues–together we can identify solutions to improve the care for those impacted by AL Amyloidosis.” — Karisa Jaramillo, Global Marketing

 

“I am hopeful that the pharma industry and legislators will continue to take actions that increase diversity and inclusion in clinical trials.” — Michael Gray, Medical Affairs